Expert Opinion on Emerging Drugs

Papers
(The median citation count of Expert Opinion on Emerging Drugs is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management40
A review of phase II and III drugs for the treatment and management of endometriosis27
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?27
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder24
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia22
New drugs targeting calcitonin gene-related peptide for the management of migraines19
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review17
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?17
Emerging biological treatments for asthma15
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials15
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials14
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia14
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape13
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms12
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials11
Emerging drugs for the treatment of herpetic keratitis11
Early investigational agents for the treatment of rosacea: drugs in phase II and III clinical development11
A review of emerging factor XI inhibitors11
Cannabinoid treatment for the symptoms of autism spectrum disorder11
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?10
Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease10
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder10
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma10
Emerging antiviral therapies and drugs for the treatment of influenza9
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion9
At the forefront of gene-based therapies in Dravet syndrome9
How will tovorafenib change our treatment of pediatric low-grade glioma?9
Correction8
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials8
Gene therapy for wet AMD: a paradigm shift in the standard of care8
Emerging drugs for the treatment of irritability associated with autism spectrum disorder8
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis8
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis7
Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond7
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials7
The role of HER2-targeted therapy in urothelial carcinomas7
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results7
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma7
Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugs7
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis7
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?6
Current and emerging drug treatment strategies to tackle sickle cell anemia6
Emerging drugs for the treatment of inflammatory bowel disease6
Emerging drugs in the treatment of chronic cough6
What can we expect from a combination of datopotamab deruxtecan, carboplatin, and pembrolizumab for brain metastases from non-small cell lung cancer?6
What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II5
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa5
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma5
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma5
Emerging drugs for the treatment of diabetic nephropathy5
Emerging small molecules for ulcerative colitis: clinical advancements and trial insights5
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond4
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder4
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E4
Emerging drugs for the treatment of alopecia areata4
Obefazimod (ABX464) for moderate-to-severe Crohn’s disease: clinical development of a novel oral therapeutic approach4
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis4
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials4
0.055459022521973